27
Participants
Start Date
January 31, 2010
Primary Completion Date
December 31, 2011
Study Completion Date
January 31, 2014
Erlotinib
Erlotinib, 150 mg, QD will be administered orally on a continuous schedule (Phase 2 only)
Erlotinib
For Phase 1 - escalating doses of erlotinib will be administered orally on a continuous schedule. The planned doses to be evaluated are 100 and 150 mg QD. The dose determined in Phase 1 will be used in Phase 2
PF-02341066
For Phase 1 - escalating doses of PF-02341066 will be administered orally on a continuous schedule. The planned doses to be evaluated are 200 and 250 mg BID. The dose determined in Phase 1 will be used in Phase 2
Holy Cross Hospital, Fort Lauderdale
University of Alabama at Birmingham, Birmingham
University of Alabama at Birmingham, Birmingham
OSU East, Columbus
The Ohio State University James Cancer Hospital, Columbus
James Care in Kenny, Columbus
Washington University, School of Medicine, St Louis
Siteman Cancer Center -West County, Creve Coeur
Siteman Cancer Center, City of Saint Peters
Cancer Therapy & Research Center @ UTHSCSA, San Antonio
University of California Irvin, Orange
Seattle Cancer Care Alliance, Seattle
University of Washington Medical Center, Seattle
University of California, Irvine Medical Center Pharmacy, Orange
University of California, Irving - Medical Center, Orange
Barnes-Jewish Hospital, St Louis
Lead Sponsor
Pfizer
INDUSTRY